Erectile dysfunction is frequent in those suffering from heart disease. It could be a good marker of an intra-clinical arterial disease. From a therapeutical point of view, intracavernous injections of PGE1 are efficient and safe second line in the treatment of erectile dysfunction in the cardiac population, whatever the origin. No drug interactions with the various treatment used in cardiology, notably derived nitrates, has been reported. Management of erectile dysfunction helps to reinforce patients' adherence to their other treatments.